NO20093146L - Amino-pyridinderivater som S1P1/EDG1-reseptoragonister - Google Patents

Amino-pyridinderivater som S1P1/EDG1-reseptoragonister

Info

Publication number
NO20093146L
NO20093146L NO20093146A NO20093146A NO20093146L NO 20093146 L NO20093146 L NO 20093146L NO 20093146 A NO20093146 A NO 20093146A NO 20093146 A NO20093146 A NO 20093146A NO 20093146 L NO20093146 L NO 20093146L
Authority
NO
Norway
Prior art keywords
amino
pyridine derivatives
receptor agonists
edg1 receptor
edg1
Prior art date
Application number
NO20093146A
Other languages
English (en)
Inventor
Martin Bolli
Oliver Nayler
Claus Mueller
Boris Mathys
Beat Steiner
Jorg Velker
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NO20093146L publication Critical patent/NO20093146L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen vedrører nye amino-pyridinderivater, deres fremstilling og deres anvendelse som farmasøytisk aktive forbindelser. Forbindelsene virker spesielt som immunmodulerende midler.
NO20093146A 2007-03-16 2009-10-15 Amino-pyridinderivater som S1P1/EDG1-reseptoragonister NO20093146L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2007050921 2007-03-16
PCT/IB2008/050742 WO2008114157A1 (en) 2007-03-16 2008-02-29 Amino- pyridine derivatives as s1p1 /edg1 receptor agonists

Publications (1)

Publication Number Publication Date
NO20093146L true NO20093146L (no) 2009-10-15

Family

ID=39500044

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20093146A NO20093146L (no) 2007-03-16 2009-10-15 Amino-pyridinderivater som S1P1/EDG1-reseptoragonister

Country Status (23)

Country Link
US (1) US8592460B2 (no)
EP (1) EP2125797B1 (no)
JP (2) JP2010521450A (no)
KR (1) KR101454944B1 (no)
CN (1) CN101627034B (no)
AR (1) AR065621A1 (no)
AU (1) AU2008227979B2 (no)
BR (1) BRPI0808789A2 (no)
CA (1) CA2679138C (no)
CY (1) CY1115087T1 (no)
DK (1) DK2125797T3 (no)
ES (1) ES2450750T3 (no)
HR (1) HRP20140335T1 (no)
IL (1) IL200911A0 (no)
MA (1) MA31290B1 (no)
MX (1) MX2009009597A (no)
NO (1) NO20093146L (no)
NZ (1) NZ580454A (no)
PL (1) PL2125797T3 (no)
PT (1) PT2125797E (no)
SI (1) SI2125797T1 (no)
TW (1) TW200902522A (no)
WO (1) WO2008114157A1 (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002593A1 (es) * 2006-09-07 2008-06-13 Actelion Pharmaceuticals Ltd Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
KR101454937B1 (ko) * 2006-09-08 2014-10-27 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-3-일 유도체
RU2442780C2 (ru) * 2006-09-21 2012-02-20 Актелион Фармасьютиклз Лтд Фенильные производные и их применение в качестве иммуномодуляторов
EP2109364A4 (en) * 2006-12-15 2010-04-14 Abbott Lab NOVEL OXADIAZONE COMPOUNDS
ATE502938T1 (de) * 2007-08-17 2011-04-15 Actelion Pharmaceuticals Ltd Pyridinderivate als s1p1/edg1-rezeptormodulatoren
JP5517944B2 (ja) * 2007-11-01 2014-06-11 アクテリオン ファーマシューティカルズ リミテッド 新規なピリミジン誘導体
US8343966B2 (en) * 2008-01-11 2013-01-01 Novartis Ag Organic compounds
ES2389042T3 (es) * 2008-03-06 2012-10-22 Actelion Pharmaceuticals Ltd. Compuestos de piridina
CN101965346A (zh) * 2008-03-06 2011-02-02 埃科特莱茵药品有限公司 新颖嘧啶-吡啶衍生物
ES2389469T3 (es) * 2008-03-07 2012-10-26 Actelion Pharmaceuticals Ltd. Derivados novedosos de aminometilbeceno
NZ588438A (en) * 2008-03-07 2012-05-25 Actelion Pharmaceuticals Ltd Pyridin-2-yl oxadiazole derivatives as immunomodulating agents
BRPI0909625B1 (pt) 2008-03-17 2021-09-08 Actelion Pharmaceuticals Ltd Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
MX354134B (es) 2008-07-23 2018-02-14 Arena Pharm Inc Derivados de acido 1,2,3,4-tetrahidrociclopenta [b] indol-3-il) acetico sustituidos utiles en el tratamiento de enfermedades autoinmune e inflamatorias.
CA2733671C (en) 2008-08-27 2018-01-02 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
AU2010220338B2 (en) * 2009-03-03 2016-07-21 Merck Serono S.A. Oxazole pyridine derivatives useful as S1P1 receptor agonists
US20100249071A1 (en) * 2009-03-30 2010-09-30 Exelixis, Inc. Modulators of S1P and Methods of Making And Using
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
DE102009002514A1 (de) * 2009-04-21 2010-10-28 Evonik Degussa Gmbh Verfahren zur Herstellung von substituierten 1,4-Chinonmethiden
KR101409131B1 (ko) * 2009-07-16 2014-06-17 액테리온 파마슈티칼 리미티드 피리딘-4-일 유도체
CN101607923B (zh) * 2009-07-21 2012-12-19 焦宁 芳基腈类化合物或其衍生物及其合成方法和应用
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
AU2010319879A1 (en) 2009-10-29 2012-06-14 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
EP4148045A1 (en) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof
SG10201501575VA (en) 2010-03-03 2015-04-29 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2560969B1 (en) 2010-04-23 2015-08-12 Bristol-Myers Squibb Company 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists
CN103124727B (zh) 2010-07-20 2015-03-25 百时美施贵宝公司 取代的3-苯基-1,2,4-噁二唑化合物
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012061459A1 (en) 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
AR084883A1 (es) * 2011-01-19 2013-07-10 Actelion Pharmaceuticals Ltd Derivados de 2-metoxi-piridin-4-ilo
RS60408B1 (sr) 2012-08-17 2020-07-31 Actelion Pharmaceuticals Ltd Postupak za pripremanje (2z,5z)-5-(3-hloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međujedinjenja upotrebljena u pomenutom postupku
TWI613182B (zh) 2013-02-21 2018-02-01 必治妥美雅史谷比公司 雙環化合物
SI2970236T1 (sl) 2013-03-15 2017-11-30 Idorsia Pharmaceuticals Ltd Derivati piridil-4-ila
TWI689487B (zh) 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US10183015B2 (en) 2015-03-04 2019-01-22 Medivation Technologies Llc Heterocyclic compounds and methods of use
JP2018507235A (ja) * 2015-03-04 2018-03-15 メディベイション テクノロジーズ エルエルシー ステロール調節エレメント結合タンパク質（ｓｒｅｂｐ）阻害剤
CN107667104B (zh) 2015-05-20 2022-03-22 爱杜西亚药品有限公司 (s)-3-{4-[5-(2-环戊基-6-甲氧基-吡啶-4-基)-[1,2,4]噁二唑-3-基]-2-乙基-6-甲基-苯氧基}-丙烷-1,2-二醇的结晶形式
US10111841B2 (en) 2015-06-19 2018-10-30 University Of South Florida Stabilization of alcohol intoxication-induced cardiovascular instability
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
WO2017004608A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Oxadiazole modulators of s1p methods of making and using
WO2017004610A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Tercyclic s1p3-sparing, s1p1 receptor agonists
WO2017004609A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Thiadiazole modulators of s1p and methods of making and using
EP3507278B1 (en) 2016-09-02 2021-01-27 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31990A (en) * 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
WO1991015583A1 (en) 1990-04-05 1991-10-17 The American National Red Cross A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
CA2051494C (en) 1990-09-20 2006-03-14 Robert J. Dinerstein 1-aryl-3-pyridinyl-2-propene-1-ones as calcium uptake inhibitors
DE4429465A1 (de) * 1994-08-19 1996-02-22 Bayer Ag Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde
EP1070080A4 (en) 1998-03-09 2004-12-29 Smithkline Beecham Corp HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
WO2000066578A1 (en) * 1999-04-30 2000-11-09 Pfizer Products Inc. Compounds for the treatment of obesity
CZ2002599A3 (cs) 1999-08-19 2002-06-12 Nps Pharmaceuticals Inc. Heteropolycyklické sloučeniny a jejich pouľití jako antagonistů metabotropního receptoru glutamátu
ES2292830T3 (es) 2001-02-21 2008-03-16 Astrazeneca Ab Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
CA2472715A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
EP1554269A1 (en) * 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
CA2524867A1 (en) * 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
EP1670463A2 (en) * 2003-10-01 2006-06-21 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
EP1697333A4 (en) * 2003-12-17 2009-07-08 Merck & Co Inc 3,4-DISUSBSTITUTED PROPANOIC CARBOXYLATES AS S1P RECEPTOR AGONISTS (EDG)
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US8022063B2 (en) 2004-05-29 2011-09-20 7Tm Pharma A/S CRTH2 receptor ligands for medicinal uses
WO2006010379A1 (en) * 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
WO2006064757A1 (ja) * 2004-12-13 2006-06-22 Ono Pharmaceutical Co., Ltd. アミノカルボン酸誘導体およびその医薬用途
EP1877388A2 (en) * 2005-02-25 2008-01-16 Kudos Pharmaceuticals Ltd Hydrazinomethyl, hydrazonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
AP2007004157A0 (en) 2005-03-17 2007-10-31 Pfizer N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
JP5072825B2 (ja) * 2005-03-23 2012-11-14 アクテリオン ファーマシューティカルズ リミテッド スフィンゴシン−１−ホスフェート−１受容体アゴニストとしての新規チオフェン誘導体
BRPI0609665A2 (pt) * 2005-03-23 2010-04-20 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
NZ562562A (en) 2005-03-23 2010-11-26 Actelion Pharmaceuticals Ltd Hydrogenated benzo(C)thiophene derivatives as immunomodulators
EP1874772A1 (en) * 2005-04-05 2008-01-09 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
CA2605594A1 (en) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Heterocyclic compound
MX2007013263A (es) 2005-04-26 2008-01-22 Neurosearch As Novedosos derivados oxadiazol y su uso medico.
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
JP2008546758A (ja) * 2005-06-24 2008-12-25 アクテリオン ファーマシューティカルズ リミテッド 新規チオフェン誘導体
WO2007001973A1 (en) 2005-06-28 2007-01-04 Astrazeneca Ab New use
AR057894A1 (es) * 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
EP1979345B1 (en) * 2006-01-24 2009-11-04 Actelion Pharmaceuticals Ltd. Novel pyridine derivatives
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
WO2007098474A1 (en) 2006-02-21 2007-08-30 University Of Virginia Patent Foundation Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists
RS20080525A (en) 2006-05-09 2009-09-08 Pfizer Products Inc., Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
AR061841A1 (es) * 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
CL2007002593A1 (es) * 2006-09-07 2008-06-13 Actelion Pharmaceuticals Ltd Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer.
KR101454937B1 (ko) * 2006-09-08 2014-10-27 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-3-일 유도체
RU2442780C2 (ru) * 2006-09-21 2012-02-20 Актелион Фармасьютиклз Лтд Фенильные производные и их применение в качестве иммуномодуляторов
BRPI0717656A2 (pt) 2006-09-29 2014-04-29 Novartis Ag Derivados de diaril oxadiazol
JP2008120794A (ja) 2006-10-16 2008-05-29 Daiichi Sankyo Co Ltd ヘテロ環化合物を含有する医薬組成物
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
EP2109364A4 (en) 2006-12-15 2010-04-14 Abbott Lab NOVEL OXADIAZONE COMPOUNDS
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
ATE502938T1 (de) * 2007-08-17 2011-04-15 Actelion Pharmaceuticals Ltd Pyridinderivate als s1p1/edg1-rezeptormodulatoren
AU2008306886B2 (en) 2007-10-04 2014-01-16 Merck Serono S.A. Oxadiazole diaryl compounds
EA201070422A1 (ru) 2007-10-04 2010-12-30 Мерк Сероно С.А. Производные оксадиазола
JP5517944B2 (ja) * 2007-11-01 2014-06-11 アクテリオン ファーマシューティカルズ リミテッド 新規なピリミジン誘導体
CA2706834A1 (en) * 2007-12-10 2009-06-18 Actelion Pharmaceuticals Ltd Thiophene derivatives as agonists of s1p1/edg1
CN101965346A (zh) * 2008-03-06 2011-02-02 埃科特莱茵药品有限公司 新颖嘧啶-吡啶衍生物
ES2389042T3 (es) * 2008-03-06 2012-10-22 Actelion Pharmaceuticals Ltd. Compuestos de piridina
ES2389469T3 (es) * 2008-03-07 2012-10-26 Actelion Pharmaceuticals Ltd. Derivados novedosos de aminometilbeceno
NZ588438A (en) * 2008-03-07 2012-05-25 Actelion Pharmaceuticals Ltd Pyridin-2-yl oxadiazole derivatives as immunomodulating agents
MY172105A (en) 2008-05-14 2019-11-14 Scripps Research Inst Novel modulators of sphingosine phosphate receptors
KR101409131B1 (ko) 2009-07-16 2014-06-17 액테리온 파마슈티칼 리미티드 피리딘-4-일 유도체

Also Published As

Publication number Publication date
AU2008227979A1 (en) 2008-09-25
HRP20140335T1 (hr) 2014-05-09
CN101627034A (zh) 2010-01-13
WO2008114157A1 (en) 2008-09-25
TW200902522A (en) 2009-01-16
CY1115087T1 (el) 2016-12-14
AU2008227979B2 (en) 2014-02-06
AR065621A1 (es) 2009-06-17
CN101627034B (zh) 2013-05-15
NZ580454A (en) 2011-05-27
KR20100014738A (ko) 2010-02-10
DK2125797T3 (da) 2014-02-10
EP2125797B1 (en) 2014-01-15
JP2010521450A (ja) 2010-06-24
MX2009009597A (es) 2009-09-16
CA2679138A1 (en) 2008-09-25
KR101454944B1 (ko) 2014-10-27
SI2125797T1 (sl) 2014-03-31
CA2679138C (en) 2015-05-26
US20100087417A1 (en) 2010-04-08
PL2125797T3 (pl) 2014-06-30
JP5588040B2 (ja) 2014-09-10
MA31290B1 (fr) 2010-04-01
ES2450750T3 (es) 2014-03-25
BRPI0808789A2 (pt) 2014-08-12
IL200911A0 (en) 2010-05-17
EP2125797A1 (en) 2009-12-02
PT2125797E (pt) 2014-03-11
US8592460B2 (en) 2013-11-26
JP2013151543A (ja) 2013-08-08

Similar Documents

Publication Publication Date Title
NO20093146L (no) Amino-pyridinderivater som S1P1/EDG1-reseptoragonister
NO20091395L (no) Nye tiofenderivater
NO20083462L (no) Nye tiofenderivater som S1P1/EDG1-reseptoragonister
NO20075298L (no) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
MY153975A (en) Pyridine derivatives as s1p1/edg1 receptor modulators
NO20083630L (no) Nye pyridinderivater
NO20082793L (no) Nye tiofenderivater
MX2010004576A (es) Derivados de pirimidina novedosos.
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
TW200942524A (en) Novel aminomethyl benzene derivatives
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
NO20076648L (no) Novel thiophene derivatives
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
CY1114759T1 (el) Παραγωγα πυριδιν-4-υλι0υ ως s1p1/edg1 αγωνιστες
NO20090628L (no) Pyridizinon derivativater
EA201170227A1 (ru) Имидазолкарбоксамиды
ATE483707T1 (de) 2-cyclopropylthiazolderivate
UA99129C2 (ru) Производные оксадиазола и их применение в качестве потенциирующих средств рецепторов глутамата
EA201100612A1 (ru) Новые производные 2-амидотиадиазола
NO20085257L (no) Purinonderivater som HM74a-agonister
NO20085099L (no) Puritonderivativer som HM74A agonister
TW200942530A (en) Pyridine compounds
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
DK2242740T3 (da) SF5-derivater som par1-inhibitorer, deres fremstilling og anvendelse som lægemidler
DK2238110T3 (da) 5.6-bisaryl-2-pyridin-carboxamid-derivater, fremstilling heraf og terapeutisk anvendelse heraf som urotensin II-receptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application